| __timestamp | Dyne Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 94103000 |
| Thursday, January 1, 2015 | 2028000000 | 146194000 |
| Friday, January 1, 2016 | 2281000000 | 130000 |
| Sunday, January 1, 2017 | 2932000000 | 7353000 |
| Monday, January 1, 2018 | 24000 | 34193000 |
| Tuesday, January 1, 2019 | 271000 | 56586000 |
| Wednesday, January 1, 2020 | 700000 | 63382000 |
| Friday, January 1, 2021 | 1088000 | 97049000 |
| Saturday, January 1, 2022 | 3345000 | 139989000 |
| Sunday, January 1, 2023 | 2461000 | 150343000 |
In pursuit of knowledge
In the ever-evolving biotech landscape, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc. from 2014 to 2023. Notably, Dyne Therapeutics experienced a dramatic fluctuation, peaking in 2017 with costs nearly 2.9 billion, before plummeting to a mere 24,000 in 2018. This volatility highlights the challenges and unpredictability in biotech operations.
Conversely, Sarepta Therapeutics showcased a more stable trajectory, with costs gradually increasing from approximately 94 million in 2014 to 150 million in 2023. This steady rise reflects a consistent growth strategy, potentially indicating robust operational management.
The contrasting trends between these two companies underscore the diverse strategies within the biotech sector, offering valuable insights for investors and industry analysts alike.
Eli Lilly and Company vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Novo Nordisk A/S vs Sarepta Therapeutics, Inc.
AstraZeneca PLC vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Pfizer Inc. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and Sarepta Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Biogen Inc. and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Sarepta Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Galapagos NV's Expenses
Cost of Revenue Comparison: ACADIA Pharmaceuticals Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Bausch Health Companies Inc. vs Dyne Therapeutics, Inc.